Cytosorbents Appoints New CMO, Elects Director
Ticker: CTSO · Form: 8-K · Filed: Aug 16, 2024 · CIK: 1175151
| Field | Detail |
|---|---|
| Company | Cytosorbents CORP (CTSO) |
| Form Type | 8-K |
| Filed Date | Aug 16, 2024 |
| Risk Level | low |
| Pages | 5 |
| Reading Time | 6 min |
| Key Dollar Amounts | $0.001, $425,000, $335 |
| Sentiment | neutral |
Sentiment: neutral
Topics: executive-appointment, board-election, governance
TL;DR
Cytosorbents just brought in a new Chief Medical Officer and added a director to the board.
AI Summary
Cytosorbents Corporation announced on August 13, 2024, the appointment of Dr. Phillip P. Chan as Chief Medical Officer and the election of Ms. Amy E. Smith to its Board of Directors. The company also disclosed compensatory arrangements for certain officers. These changes are effective as of the reporting date.
Why It Matters
These executive and board changes could signal a shift in the company's strategic direction or focus on medical innovation and governance.
Risk Assessment
Risk Level: low — The filing primarily concerns executive appointments and board changes, which are routine corporate governance events.
Key Players & Entities
- Cytosorbents Corporation (company) — Registrant
- Dr. Phillip P. Chan (person) — Appointed Chief Medical Officer
- Ms. Amy E. Smith (person) — Elected to Board of Directors
FAQ
Who has been appointed as the new Chief Medical Officer?
Dr. Phillip P. Chan has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors?
Ms. Amy E. Smith has been elected to the Board of Directors.
What is the effective date of these changes?
The earliest event reported is dated August 13, 2024.
What other information is disclosed regarding officers?
The filing also discloses compensatory arrangements of certain officers.
What is the state of incorporation for Cytosorbents Corporation?
Cytosorbents Corporation is incorporated in Delaware.
Filing Stats: 1,608 words · 6 min read · ~5 pages · Grade level 11.4 · Accepted 2024-08-16 17:12:04
Key Financial Figures
- $0.001 — e on which registered Common Stock, $0.001 par value CTSO The Nasdaq Stock Marke
- $425,000 — i will receive an annual base salary of $425,000 and will be eligible to receive an annu
- $335 — ill be compensated at an hourly rate of $335 per hour. Restricted stock units awarde
Filing Documents
- tm2421901d1_8k.htm (8-K) — 42KB
- tm2421901d1_ex10-1.htm (EX-10.1) — 117KB
- tm2421901d1_ex10-2.htm (EX-10.2) — 50KB
- tm2421901d1_ex10-3.htm (EX-10.3) — 68KB
- tm2421901d1_ex10-4.htm (EX-10.4) — 70KB
- tm2421901d1_ex10-5.htm (EX-10.5) — 24KB
- tm2421901d1_ex99-1.htm (EX-99.1) — 19KB
- image_003.jpg (GRAPHIC) — 34KB
- 0001104659-24-090567.txt ( ) — 698KB
- ctso-20240813.xsd (EX-101.SCH) — 3KB
- ctso-20240813_lab.xml (EX-101.LAB) — 33KB
- ctso-20240813_pre.xml (EX-101.PRE) — 22KB
- tm2421901d1_8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: August 16, 2024 CYTOSORBENTS CORPORATION By: /s/ Dr. Phillip P. Chan Name: Dr. Phillip P. Chan Title: Chief Executive Officer